On July 28, BEIGENE fell 3.15% in regular trading, trading at 193.4 HKD/share, with turnover of 4.41 billion HKD. The decline came amid a broad pullback across the biotechnology sector following an extended rally.

On the news front, the Hang Seng Healthcare Index had accumulated a 17.4% gain over the prior month, significantly outperforming the broader market, intensifying profit-taking pressure. Sector peers declined broadly, with LEADS BIOLABS-B down 8.35%, KEYMED BIO-B down 5.22%, AKESO down 3.55%, and 3SBIO down 1.23%.

At the company level, BEIGENE previously disclosed that a domestic subsidiary is required to pay approximately 446 million RMB in back taxes and late fees, which will be recorded as a current-period expense, weighing on near-term profitability. With the company scheduled to release second-quarter results on August 5, the approaching earnings date combined with significant prior gains has fueled profit-taking sentiment among investors.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)